The mission of SWOG is to improve the practice of medicine in detecting, preventing, and treating cancer. The SWOG Cancer Control Research Base supports this mission through the development, conduct, analysis, and publication of clinical trials in cancer treatment, control and prevention as well as associated research. On average SWOG manages 50 on-going protocols and recruits 5-15,000 patients or subjects yearly to its trials. Under the direction of the Group Chair, the Associate Chair for Cancer Control and Prevention sets the scientific agenda for cancer control and prevention (CCP) within SWOG, which is implemented within five CCP committees;Prevention, Molecular Epidemiology, Cancer Survivorship, Symptom Management and Quality of Life, and Outcomes and Comparative Effectiveness. Often in partnership one of the eight SWOG disease oriented committees (Breast, Gastrointestinal, Genitourinary, Leukemia, Lung, Lymphoma, Melanoma, and Myeloma). The investigators within CCP develop and conduct research that is relevant, innovative and translatable. Additionally, SWOG manages and supports a large set of biorepositories and the infrastructure to provide these clinically annotated specimens to the research community at large. Further, SWOG will provide a unique resource to the research community through the development of a Cancer Comparative Effectiveness Research Center (CCERC) to provide facilitate the prioritization, design, implementation and translation of prospective comparative effectiveness trials within the NCI cooperative group network. The CCERC will become a model infrastructure within the NIH for leveraging burgeoning opportunities in comparative effectiveness research, including the new Patient Centered Outcomes Research Institute (PCORI) and commercial health insurer's movement towards coverage with evidence development funding models. The SWOG Research Base is partnered with 26 Community Clinical Oncology Programs (CCOP) or Minority Based CCOP and approximately 35% of its total accrual comes from the CCOP program. CCOP physicians play a leadership role within the group structure.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Minasian, Lori M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Christen, William G; Glynn, Robert J; Gaziano, J Michael et al. (2015) Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. JAMA Ophthalmol 133:17-24
Unger, Joseph M; Barlow, William E; Martin, Diane P et al. (2014) Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 106:dju002
Gurel, Bora; Lucia, M Scott; Thompson Jr, Ian M et al. (2014) Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 23:847-56
Schenk, Jeannette M; Till, Cathee A; Tangen, Catherine M et al. (2014) Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 23:1484-93
Albanes, Demetrius; Till, Cathee; Klein, Eric A et al. (2014) Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila) 7:886-95
Ankerst, Donna P; Hoefler, Josef; Bock, Sebastian et al. (2014) Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83:1362-7
Kristal, Alan R; Darke, Amy K; Morris, J Steven et al. (2014) Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 106:djt456
Figg, William D; Chau, Cindy H; Price, Douglas K et al. (2014) Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. Urology 84:127-31
Kristal, Alan R; Till, Cathee; Song, Xiaoling et al. (2014) Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 23:1494-504
Gritz, Ellen R; Arnold, Kathryn B; Moinpour, Carol M et al. (2014) Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiol Biomarkers Prev 23:1638-48

Showing the most recent 10 out of 292 publications